恒瑞医药(600276.SH)：获得HRS-8364片的临床试验批准通知书

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for the clinical trial of HRS-8364 tablets, an innovative anti-tumor drug aimed at treating advanced solid tumors, with no similar drugs approved in the market currently [1] Group 1 - The drug HRS-8364 is developed independently by the company and is intended for the treatment of advanced solid tumors [1] - The total research and development investment for HRS-8364 has reached approximately 21.65 million yuan [1] - Following the approval of the clinical trial notification, the drug must undergo clinical trials and receive further review and approval from the National Medical Products Administration before it can be manufactured and marketed [1]